Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.

 

Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

Bristol-Myers Squibb expands International Immuno-Oncology Network (II-ON)

Alzheimer's drug prescribed off-label could pose risk for some

CUBE Tech Fair welcomes spectacular speakers

Ronald E. Blaylock elected to Pfizer's Board of Directors

Drugs similar to aspirin, ibuprofen could help treat sepsis, study suggests

Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastat …

Another record year for Bayer – good progress with the acquisition of Monsanto

Successful insomnia treatment may require nothing more than a placebo

Bristol-Myers Squibb appoints three new independent directors

Online pharmacies could fuel antibiotic resistance

Vitamin D protects against colds and flu, finds major global study

AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada

Your computer can help scientists search for new childhood cancer treatments

DNA computer brings 'intelligent drugs' a step closer

Spider web of cancer proteins reveals new drug possibilities

Merck's letermovir aces bone marrow transplant study, cutting death rate

Advaxis pens backloaded $358M cancer delivery tech deal

Pharma Two B raises $30M for Parkinson's phase 3 from Biogen-backed fund, adds ex-Pfizer CEO to …

La Jolla hits endpoint in phase 3 CRH test, preps for FDA talks

Exonics to use CRISPR in an effort to treat majority of DMD boys

Pfizer, Celgene-backed upstart Arrakis hopes to mine RNA spice

Delay to hep C drug program behind Merck's write-down decision, say analysts

AstraZeneca’s FDA delayed ZS-9 gains European thumbs-up

Patient death in phase 3 raises doubts about safety of Roche’s potential hemophilia blockbuster emic …

Celgene president, COO Jackie Fouse to make shock departure

J&J leads $25M Series A in targeted radiotherapy startup

Chutes & Ladders: FDA’s personalized medicine head leaves for Grail

Incyte pens cancer I-O pact with University of Pennsylvania’s cancer center

Aveo takes baby step forward for once-rejected tivozanib

Cyclacel AML drug fails phase 3, wiping 30% off stock

Combination therapies: the new standard in treating chronic illnesses

J&J says its average drug price hikes were 3.5% in 2016

Advaxis rises as it out-licenses delivery technology for novel cancer immunotherapy

Almirall’s stock hit hard as income drops by 43%

Collaboration for late-stage combination trial in first-line kidney cancer

Merck writes off $2.9 billion amid falling HCV sales

$288 million Franco-Swiss biologics production facility collaboration

New measures proposed in Greece could mean a pharmaceutical “Grexit,” says trade group

Cempra shares rise a quarter on Phase III success

Cyclacel shares fall a quarter on Phase III failure

Recordati gains rights to ROP drug know-how

FTC approves final order preserving competition in US markets for animal health products

Look back at pharma news to Feb 24

Four new drugs backed for approval, including one orphan, by EMA/CHMP

Extensions of indications recommended by EMA/CHMP for three drugs

Medical News Today: Can red ginseng help treat erectile dysfunction?

Medical News Today: Prebiotics could stop stress from harming sleep quality

Medical News Today: Nasal swab could help diagnose lung cancer

Medical News Today: Cancer: New way of tracking rare T cells should improve immunotherapy

Medical News Today: Microgreens: Health benefits and growing tips

Medical News Today: Six herbs for treating erectile dysfunction

Medical News Today: Chronic stress may raise obesity risk

Medical News Today: Mothers, not fathers, get less sleep when living with children

Medical News Today: Propranolol: Uses, benefits, and side effects

Medical News Today: Do men and women respond differently to heat? Study investigates

Medical News Today: Why am I impotent? Common causes and treatments

Medical News Today: Multiple sclerosis: New technology improves cognition

Medical News Today: HIV vs. AIDS: Differences and connections

Medical News Today: Neurofeedback treatment for insomnia no better than placebo

Medical News Today: Cats do not harm children's mental health, study finds

NHS funding cleared for new specialised treatments

Six new medicines endorsed for EU approval

EU expands use of Revlimid to include post ACST use

Merck gears up to file antiviral letermovir in the US, EU

Manchester to explore new ways of paying for medicines

Better diabetic foot care 'could save NHS £250m'

Tickets available for Clinical Researcher of the Year – The Americas

Celebrating excellence in international clinical research

Novartis’ Afinitor gets NICE green light for kidney cancer

Mundipharma to launch Mabthera biosimilar in EU markets

Bowel scope screening cuts cancer and death rate

US priority review for Novartis’ lung cancer drug Zykadia

Priority review for Pfizer’s ALL drug

MSD, Wayra unveil Velocity Health winners

EU nod for Roche’s lung cancer drug Alecensa

More News